Plasma levels of lipoprotein (a) in @entity1 with major XXXX .

@entity1 @entity308 @entity301 @entity3452 @entity2101 @entity731 @entity65 @entity165
@entity308 and @entity65 are among the most prevalent health problems. The evidence that @entity308 is a risk factor for the development and progression of @entity301 has strengthened over the past several years, but the exact reasons are not yet clear. @entity2101 (a) ( @entity3452 ) concentrations seem to be the major factor for the progression of the @entity731 and @entity301 . In this study, we measured the plasma levels of @entity3452 in 35 @entity1 with @entity308 and 35 healthy controls. The two groups were matched by age and gender. @entity3452 measurement was performed using an immunoturbidimetric method. Total @entity165 was significantly lower in the @entity1 group (mean +/-SD: 144.65+/-22.13 vs. 186.14+/-34.48 mg/dl. The @entity3452 levels of the @entity1 group differed significantly from control values. @entity1 with @entity308 had higher plasma levels of @entity3452 than healthy controls (34.94+/-18.01 vs. 20.08+/-11.27 mg/dl). The results of the present study suggest that the increase of @entity3452 may contribute to higher cardiovascular risk in @entity1 with @entity308 .
